Send to

Choose Destination
Contraception. 2019 Jan 23. pii: S0010-7824(19)30014-9. doi: 10.1016/j.contraception.2019.01.001. [Epub ahead of print]

Rebound of medication abortion in Texas following updated mifepristone label.

Author information

Texas Policy Evaluation Project, Austin, TX; Ibis Reproductive Health, Oakland, CA. Electronic address:
Texas Policy Evaluation Project, Austin, TX; Department of Health Care Organization and Policy, School of Public Health, University of Alabama at Birmingham, Birmingham, AL.
Texas Policy Evaluation Project, Austin, TX; Population Research Center, University of Texas at Austin, Austin, TX.
Texas Policy Evaluation Project, Austin, TX; Advancing New Standards in Reproductive Health (ANSIRH), Bixby Center for Global Reproductive Health, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, Oakland, CA.



In 2013, Texas House Bill 2 (HB 2) placed restrictions on the use of medication abortion, which later were nullified with the 2016 FDA-approved mifepristone label.


Using data collected directly from Texas abortion facilities, we evaluated changes in the provision and use of medication abortion during three 6-month time periods corresponding to the policy changes: before HB 2, after HB 2 and after the label change.


Medication abortion constituted 28% of all abortions before HB 2, 10% after implementation of the restrictions and 33% after the label change.


Use of medication abortion in Texas rebounded after the FDA label change.


Abortion restrictions; House Bill 2; Medication abortion; Mifepristone; Texas

Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center